Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug

Key Takeaways KYMR reported positive phase I results for KT-621, showing strong STAT6 degradation in blood and skin The oral STAT6 degrader matched or outperformed Dupixent on Th2 biomarkers like TARC and Eotaxin-3. KT-621 showed a placebo-like safety profile with no serious adverse events across escalating dose cohortsKymera Therapeutics, Inc. (KYMR) announced positive clinical results from the phase I study on the investigational candidate, KT-621.Shares surged as data surpassed the company’s expectatio ...